MARKET

FOMX

FOMX

Foamix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.990
-0.190
-4.55%
After Hours: 4.040 +0.05 +1.25% 16:57 01/29 EST
OPEN
4.180
PREV CLOSE
4.180
HIGH
4.210
LOW
3.960
VOLUME
272.29K
TURNOVER
--
52 WEEK HIGH
4.840
52 WEEK LOW
1.970
MARKET CAP
245.71M
P/E (TTM)
-3.0716
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FOMX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

FOMX News

  • SHAREHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Merger
  • ACCESSWIRE.01/22 18:00
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.01/17 13:07
  • Foamix Reports OrbiMed Advisors Intends To Vote In Favor Of Proposed Merger With Menlo
  • Benzinga.01/17 13:02
  • Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics
  • GlobeNewswire.01/17 13:00

More

Industry

Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About FOMX

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
More

Webull offers Foamix Pharmaceuticals Ltd (FOMX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.